95 related articles for article (PubMed ID: 16397284)
1. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women.
Gardner M; Taylor A; Wei G; Calcagni A; Duncan B; Milton A
J Clin Pharmacol; 2006 Jan; 46(1):52-8. PubMed ID: 16397284
[TBL] [Abstract][Full Text] [Related]
2. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.
Roman D; Bramson C; Ouellet D; Randinitis E; Gardner M
J Clin Pharmacol; 2005 Dec; 45(12):1407-12. PubMed ID: 16291716
[TBL] [Abstract][Full Text] [Related]
3. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
4. Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects.
Prakash C; Johnson KA; Gardner MJ
Drug Metab Dispos; 2008 Jul; 36(7):1218-26. PubMed ID: 18372400
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of lasofoxifene in Japanese and white postmenopausal women.
Fountaine RJ; Nishizawa Y; Wei G; Dogolo L; Calcagni A; Gardner MJ
J Clin Pharmacol; 2006 Jun; 46(6):693-9. PubMed ID: 16707415
[No Abstract] [Full Text] [Related]
6. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
7. Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats.
Terry KK; Cappon GD; Hurtt ME; Tassinari MS; Gupta U
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):150-60. PubMed ID: 15282736
[TBL] [Abstract][Full Text] [Related]
8. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
9. Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.
Moller RA; Fisher JM; Taylor AE; Kolluri S; Gardner MJ; Obach RS; Walsky RL
Ann Pharmacother; 2006 Jan; 40(1):32-7. PubMed ID: 16368922
[TBL] [Abstract][Full Text] [Related]
10. Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys.
Lees C; Shen V; Brommage R
Menopause; 2007; 14(1):97-105. PubMed ID: 17075430
[TBL] [Abstract][Full Text] [Related]
11. Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits.
Ozolins TR; Gupta U
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):161-70. PubMed ID: 15282737
[TBL] [Abstract][Full Text] [Related]
12. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Peterson GM; Naunton M; Tichelaar LK; Gennari L
Ann Pharmacother; 2011 Apr; 45(4):499-509. PubMed ID: 21467260
[TBL] [Abstract][Full Text] [Related]
13. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.
Visser M; Holinka CF; Coelingh Bennink HJ
Climacteric; 2008; 11 Suppl 1():31-40. PubMed ID: 18464021
[TBL] [Abstract][Full Text] [Related]
14. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
Gennari L
Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
16. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys.
Prakash C; Johnson KA; Schroeder CM; Potchoiba MJ
Drug Metab Dispos; 2008 Sep; 36(9):1753-69. PubMed ID: 18515329
[TBL] [Abstract][Full Text] [Related]
17. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator.
Skrumsager BK; Kiehr B; Pedersen PC; Gerrits M; Watson N; Bjarnason K
Br J Clin Pharmacol; 2002 Mar; 53(3):284-95. PubMed ID: 11874392
[TBL] [Abstract][Full Text] [Related]
18. Lasofoxifene (Pfizer).
Gennari L
Curr Opin Investig Drugs; 2005 Oct; 6(10):1067-78. PubMed ID: 16259229
[TBL] [Abstract][Full Text] [Related]
19. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
Gennari L
Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
Conlan MG; de Vries EFJ; Glaudemans A; Wang Y; Troy S
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):675-689. PubMed ID: 32661909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
